4Q preview: Amgen, Biogen, BMS, Celgene, Novartis, Pfizer and Roche
This article was originally published in Scrip
Executive Summary
The full-year reporting season began on 21 January with Johnson & Johnson reporting a strong showing from pharma sales (helped from an expected short-lived boost from its hepatitis C newcomer Olysio (simeprevir). Its fourth-quarter figures already showed the effects of "currency headwinds" that are expected to impact many in its pharma peer set in 2015. It warned that foreign exchange shifts with the recent strong appreciation of the US dollar will weigh on its 2015 figures. Goldman Sachs analysts believe big US pharma companies will take a 4-6% hit from currency headwinds in 2015, with about 37-50% of the top line hit flowing to EPS.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.